XML 20 R6.htm IDEA: XBRL DOCUMENT v3.19.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Cash flows from operating activities:    
Net loss $ (12,634) $ (22,686)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,004 2,151
Amortization of deferred financing costs and debt discount 578 707
In process research and development acquired from Azaya Therapeutics 0 1,686
Change in fair value of warrants (2,233) 0
Allocation of issuance cost associated with warrants 470 0
Provision for doubtful accounts 18 0
Provision for excess inventory 463 340
Share-based compensation expense 355 753
Loss (gain) on asset disposal 36 (42)
Increases (decreases) in cash caused by changes in operating assets and liabilities:    
Accounts receivable (173) 1,129
Inventories 475 251
Other current assets 85 (593)
Other assets 23 (94)
Accounts payable and accrued expenses (1,532) (1,817)
Deferred revenues 73 (3)
Long-term deferred rent and other 17 90
Net cash used in operating activities (11,975) (18,128)
Cash flows from investing activities:    
Proceeds from sale of assets 0 113
Net cash used in investing activities (133) (1,383)
Cash flows from financing activities:    
Principal payments on long-term obligations 0 (4,720)
Financed capital expenditures (66) 0
Proceeds from sale of common and preferred stock 8,766 23,613
Costs from sale of common and preferred stock (1,532) (2,078)
Net cash provided by financing activities 7,168 16,815
Effect of exchange rate changes on cash and cash equivalents 16 11
Net decrease in cash and cash equivalents (4,924) (2,685)
Cash, cash equivalents, and restricted cash at beginning of period 10,225 12,910
Cash, cash equivalents, and restricted cash at end of period 5,301 10,225
Cash paid during period for:    
Interest 1,331 1,364
Supplemental schedule of non-cash investing and financing activities:    
Conversion of preferred stock into common stock 8 23
Fair value of Series C and Series B Convertible Preferred Stock beneficial conversion feature 2,487 3,977
Property Plant And Equipment Excluding Research Lab Equipment And Leasehold Improvements [Member]    
Cash flows from investing activities:    
Purchases of property and equipment /long-lived assets (133) (295)
Assets Purchased from Azaya Therapeutics, Inc. [Member]    
Cash flows from investing activities:    
Purchases of property and equipment /long-lived assets 0 (1,201)
Supplemental schedule of non-cash investing and financing activities:    
Common stock issued in payment for the assets acquired $ 0 $ 2,311